For the research, 2,260 adolescents aged between 12 to 15 years, of which 1,131 got the vaccine (BNT162b2) and 1,129 got a placebo.
The research was performed within the US, which has already began the vaccination for adolescents above the age of 12 in mid-Could after the Middle for Illness Management and Prevention accepted the Pfizer vaccine for this age group.
Different nations which have accepted the Pfizer vaccine for adolescents above the age of 12 embrace Chile, Canada, Japan and Italy. Dubai and Philippines have accepted the vaccine for emergency use.
The research
Among the many 2,260 individuals, 51 per cent had been male, 86 per cent had been White and 12 per cent had been Hispanic or Latinx. Total, 1,308 individuals had at the very least two months of follow-up after their second dose of vaccination.
The vaccine’s reactogenicity (the diploma to which a vaccine can produce an extreme immune response and antagonistic reactions) and immunogenicity (the flexibility to elicit an immune response in opposition to a pathogen) was in contrast with that of one other cohort, of individuals aged between 16 to 25 years.
In each age teams, headache and fatigue had been probably the most generally reported systemic occasions. After BNT162b2 injection, extreme headache and fatigue had been reported in a decrease share of 12-15-year-old individuals than of 16-25-year-old individuals. The immune response to BNT162b2 in 12-15 yr previous adolescents was non-inferior in comparison with 16-25-year-old younger adults.
The noticed vaccine efficacy was 100 per cent, stated the research.
Source link
